Satsuma Pharmaceuticals, Inc.
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY22 | FY21 | FY20 | FY19 | FY18 | |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Operating income | −$70.9M | −$51.2M | −$48.3M | −$2.7M | −$1.4M |
| Net income | −$70.1M | −$51.2M | −$47.6M | −$2.8M | −$1.2M |
| Total assets | $54.9M | $109.8M | $81.0M | $126.3M | $6.4M |
| Total liabilities | $8.1M | $8.5M | $9.1M | $10.9M | $6.9M |
| Equity | $46.8M | $101.3M | $71.9M | $115.3M | −$12.1M |
| EPS (diluted) | $-2.19 | $-1.75 | — | — | — |
| Shares out. | 31.5M | 31.5M | 17.4M | 17.4M | 1.1M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2022- Operating margin
- —
- Net margin
- —
- Return on equity
- −149.6%
- Return on assets
- −127.5%
- Return on capital (ROCE)
- −151.5%
- Liabilities / assets
- 14.8%
- Debt / equity
- 0.17×
- Book value / share
- $1.48
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2022- Altman Z″ (distress)
- -9.61distress
- Accruals / assets
- −33.7%clean
- Piotroski F-Score
- 1/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 1 warning● 2 good- Altman Z″ in the distress zone
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Ra Capital Management, L.P. | Jun 8, 2023 | U | 5.9M | — |
| O'Neil Thomas P.Officer — Chief Financial Officer | Jun 6, 2023 | U | 13,877 | $0.91 |
| Shah Rajeev M.Director | Jun 6, 2023 | U | 5.9M | $0.91 |
| Takanashi KenDirector | Jun 6, 2023 | Buy | 22.1M | $0.91 |
| Kollins John AOfficer — President and CEO | Jun 6, 2023 | U | 305,911 | $0.91 |
| Shin Nippon Biomedical Laboratories, Ltd.10% owner | Jun 6, 2023 | Buy | 22.1M | $0.91 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Terminated a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsJun 8, 2023
- Other material eventMay 18, 2023
- Other material eventMay 3, 2023
- Entered a material agreement · Delisting / listing-standard notice · Director / officer change · Regulation FD disclosureApr 17, 2023
- Results of operationsMar 28, 2023
- Other material eventFeb 16, 2023
- Other material eventDec 20, 2022
- Other material eventNov 30, 2022
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 15-12GJun 20, 2023
- SC 13G/ANONEJun 13, 2023
- 4OWNERSHIP DOCUMENTJun 12, 2023
- SC 13D/AJun 12, 2023
- EFFECTJun 8, 2023
- EFFECTJun 8, 2023
- EFFECTJun 8, 2023
- 4FORM 4 SUBMISSIONJun 8, 2023
- 4FORM 4 SUBMISSIONJun 8, 2023
- 4FORM 4 SUBMISSIONJun 8, 2023
- 4FORM 4 SUBMISSIONJun 8, 2023
- 4FORM 4 SUBMISSIONJun 8, 2023
- 4FORM 4 SUBMISSIONJun 8, 2023
- 4FORM 4 SUBMISSIONJun 8, 2023
- 4FORM 4 SUBMISSIONJun 8, 2023
Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.